

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies














